ANIWELYN TAN: Open Payments
NPI 1477056356 · SHERMAN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,087 in 29 payments from 13 companies in 2025. Trend: 2023 $3,086 · 2024 $2,101 · 2025 $2,087
Food & beverage: $2,087
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 3 | $367 |
| Dexcom, Inc. | 3 | $296 |
| Abbott Laboratories | 3 | $286 |
| Teva Pharmaceuticals USA, Inc. | 3 | $165 |
| ABBVIE INC. | 6 | $164 |
| Novo Nordisk Inc | 2 | $142 |
| GENZYME CORPORATION | 1 | $122 |
| Lilly USA, LLC | 1 | $122 |
| AstraZeneca Pharmaceuticals LP | 1 | $122 |
| Grifols USA, LLC | 1 | $116 |
Products named: DEXCOM G7 GSS (161), FREESTYLE LIBRE 3, KRYSTEXXA, VRAYLAR, AUSTEDO XR, Ozempic, FABRAZYME, OTEZLA.
Industry payments across TX — which companies pay providers there.
